NCT05537142View on ClinicalTrials.gov

A Study to Assess the Phamacokinetics of BV100 in Participants with Varying Degrees of Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 2, 2022

Primary Completion Date

July 30, 2024

Study Completion Date

October 30, 2024

Conditions
Healthy Participants
Interventions
DRUG

BV100

Rifabutin for Infusion

Trial Locations (1)

H-2143

CRU Hungary Kft., Early Phase Unit, Kistarcsa

Sponsors

Lead Sponsor

BioVersys AG
All Listed Sponsors
collaborator

Clinical Research Units Hungary

OTHER

lead

BioVersys AG

INDUSTRY